AbbVie, Vertex Pharmaceuticals, Thermo Fisher Scientific, argenx, and Oddity Tech are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that research, develop, and commercialize products based on biological processes—ranging from pharmaceuticals and gene therapies to diagnostics and agricultural biotech. They typically carry high growth potential because clinical trial successes or regulatory approvals can sharply boost valuation, but they also involve substantial R&D costs, uncertain regulatory outcomes, and binary trial results, making them more volatile than many other sectors. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of AbbVie stock traded down $2.11 during midday trading on Tuesday, reaching $187.96. The company had a trading volume of 2,868,062 shares, compared to its average volume of 7,263,517. AbbVie has a 1-year low of $153.58 and a 1-year high of $218.66. The company has a market capitalization of $332.50 billion, a price-to-earnings ratio of 78.32, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The stock has a fifty day simple moving average of $193.79 and a 200 day simple moving average of $187.23.
Read Our Latest Research Report on ABBV
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
VRTX stock traded down $1.29 during midday trading on Tuesday, reaching $438.08. The company's stock had a trading volume of 1,146,352 shares, compared to its average volume of 1,393,046. The business's 50-day simple moving average is $487.70 and its 200-day simple moving average is $465.56. The stock has a market cap of $112.50 billion, a PE ratio of -199.13, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals has a 52 week low of $377.85 and a 52 week high of $519.88. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01.
Read Our Latest Research Report on VRTX
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
TMO stock traded down $0.14 during midday trading on Tuesday, hitting $432.45. The company's stock had a trading volume of 1,091,722 shares, compared to its average volume of 1,804,742. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific has a twelve month low of $401.75 and a twelve month high of $627.88. The company's fifty day moving average price is $462.82 and its 200 day moving average price is $513.70. The stock has a market capitalization of $163.25 billion, a P/E ratio of 26.16, a PEG ratio of 2.99 and a beta of 0.82.
Read Our Latest Research Report on TMO
argenx (ARGX)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Shares of argenx stock traded down $16.61 during trading on Tuesday, hitting $544.29. 404,523 shares of the stock were exchanged, compared to its average volume of 320,325. The stock has a market capitalization of $33.23 billion, a price-to-earnings ratio of -618.51 and a beta of 0.57. The company has a fifty day moving average price of $594.76 and a 200-day moving average price of $613.84. argenx has a 1-year low of $352.77 and a 1-year high of $678.21.
Read Our Latest Research Report on ARGX
Oddity Tech (ODD)
Oddity Tech Ltd. operates as a consumer tech company that builds digital-first brands for the beauty and wellness industries in the United States and internationally. It serves consumers worldwide through its AI-driven online platform, which uses data science, machine learning, and computer vision capabilities to identify consumer needs, and develop solutions in the form of beauty and wellness products.
Shares of ODD stock traded down $8.85 during midday trading on Tuesday, hitting $61.23. 3,304,317 shares of the company were exchanged, compared to its average volume of 558,085. The firm has a market capitalization of $3.42 billion, a P/E ratio of 37.34, a PEG ratio of 1.48 and a beta of 3.44. The firm's 50 day moving average price is $47.18 and its two-hundred day moving average price is $45.35. Oddity Tech has a 52 week low of $32.71 and a 52 week high of $73.00.
Read Our Latest Research Report on ODD
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
